MA11.11 STK11/LKB1 Genomic Alterations Are Associated with Inferior Clinical Outcomes with Chemo-Immunotherapy in Non-Squamous NSCLC

In This Issue/Research Watch/News-in-Brief/News from 002the IASLC Tobacco Control Committee

“…"We do not expect everyone engaged in tobacco control to be convinced.but we do invite.an open mind .. and [tolerance of] any early missteps as we find our feet!" 6(para.21) In these statements the President of the Foundation is asking us, his readers, to accept the Foundation's mission, to ignore the activities of PMI in undermining tobacco control through litigation 10 , to ignore its disparaging view of the FCTC evident in the Reuters' Phillip Morris Files 11 and to ignore continued tobacco cigarettes sales in lower and middle income countries where tobacco control measures are relatively weak. 12 PMIs 137-page white paper uses similar strategies, sprinkling reassuring images of nature amongst text that creates new language ("unsmoke" 1(p.1) ), that reports the findings of an industry-funded survey of smokers and their preferences and that in the words of another Lancet editorial, neatly and characteristically, "disentangles PMI from any public health responsibility" 13(para.3) and deploys:…”

“…The poorer outcome in STK11 mutant tumors across treatment arms in patients with advanced NSCLC has also been reported in MYSTIC trial 9 , as well as, it has been reported a negative predictive marker for PFS in non-squamous NSCLC treated with pembrolizumab and chemotherapy regardless of PD-L1 expression. 10 Data are limited for immunotherapy in patients with advanced NSCLC and poor performance status or other comorbidities. CheckMate 817 11 is a multi-cohort, open-label phase 3b/4 study investigating safety and efficacy of nivolumab 240 mg Q2W plus ipilimumab 1 mg/kg Q6W for two years or until progression or unacceptable toxicity.…”